Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma | MicrobiomeTrials← Back to trialsNCT04930653
Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2022-10-19Est. Completion: 2028-06-15
Enrollment target: 34 participants Locations- Mayo Clinic, Scottsdale, Arizona, United States
- City of Hope Medical Center, Duarte, California, United States
- Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
Other microbiome trials you might be interested in
Folliculotropic Mycosis FungoidesRecurrent Cutaneous T-Cell Non-Hodgkin LymphomaRecurrent Mycosis FungoidesRefractory Cutaneous T-Cell Non-Hodgkin LymphomaRefractory Mycosis FungoidesRefractory Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedSezary SyndromeRecurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma
This randomized phase I/II trial studies the best dose and side effects of durvalumab and to see how well it works with …
Duarte, United StatesEst. completion Apr 14, 2030
Chronic Spontaneous Urticaria (CSU)Hidradenitis Suppurativa (HS)Psoriasis (PsO)Atopic Dermatitis (AD)CTCL/ Mycosis Fungoides
The goal of this observational study is to comprehensively profile six immune-mediated inflammatory diseases, including …
Nijmegen, NetherlandsEst. completion Dec 31, 2029